#USA #New York #Class Action #Lawsuit #INOVIO Pharmaceuticals

Class Action Filed Against Inovio Pharmaceuticals

On February 18, 2026, Levi & Korsinsky, LLP announced a class action lawsuit against Inovio Pharmaceuticals, Inc., known by its stock ticker INO, which is traded on the NASDAQ exchange. This lawsuit pertains to alleged securities fraud that has adversely affected investors between the dates of October 10, 2023, and December 26, 2025.

Background of the Case

The essence of the lawsuit arises from claims that certain false statements were made by the defendants, which misrepresented the true manufacturing status of Inovio's CELLECTRA device. Specifically, the complaint alleges that the manufacturing processes were indeed deficient, raising significant concerns regarding the corporate leadership's transparency and commitment to regulatory standards.

As a result of these purported misstatements, the filing further suggests that Inovio was unlikely to submit its lead product candidate, INO-3107, to the FDA by the proposed timeline expected in the second half of 2024. Furthermore, the case casts doubt on whether Inovio had adequate information to advocate for the eligibility of the INO-3107 for expedited FDA approval, including accelerated pathways that are generally reserved for groundbreaking treatments.

Why You Should Pay Attention

The implications of this case could be significant for shareholders. If you have experienced financial losses during the stated period, you are encouraged to consider joining the lawsuit to seek recompense. The deadline to join the class action is set for April 7, 2026. It's important to note that potential plaintiffs need not bear any costs upfront to participate in this class action.

How to Get Involved

Those interested in participating can find additional information and connect with representatives of Levi & Korsinsky through their official submission form available on their website. Alternatively, individuals can directly reach out via email at [email protected] or call Joseph E. Levi, Esq. at (212) 363-7500 for personalized consultation regarding their situation.

Levi & Korsinsky's Track Record

Levi & Korsinsky, with over 20 years of experience, boasts an impressive record of retrieving hundreds of millions of dollars for investors in similar cases. The firm specializes in complex securities litigation and has a dedicated team of over 70 professionals working to ensure clients receive the utmost support and representation. Their reputation is bolstered by consistent rankings among the top securities litigation firms in the United States by ISS Securities Class Action Services.

For those standing to lose financially due to this unfortunate turn of events with Inovio Pharmaceuticals, it is crucial to act swiftly. Engaging with this legal opportunity could pave the way for potential recovery and vindication of your investment. Remember, while you have until April 7, 2026, to file your claim, early action could provide you with a strategic advantage in navigating this lawsuit.